Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection  by Cordero, E. et al.
Pandemic inﬂuenza A(H1N1) virus infection in solid organ transplant
recipients: impact of viral and non-viral co-infection
E. Cordero1, P. Pe´rez-Romero1, A. Moreno2, O. Len3, M. Montejo4, E. Vidal5, P. Martı´n-Da´vila6, M. C. Farin˜as7,
N. Ferna´ndez-Sabe´8, M. Giannella9, J. Pacho´n1 and The Novel inﬂuenza A(H1N1) Study Group of the Spanish Network for
Research in Infectious Diseases (REIPI)*
1) Infectious Diseases Unit, Hospital Universitario Virgen del Rocı´o, Instituto de Biomedicina Sevilla (IBiS), Sevilla, Spain, 2) Infectious Diseases Unit, Hospital
Clinic, Barcelona, Spain 3) Infectious Diseases Unit, Hospital Vall d¢Hebron, Barcelona, Spain 4) Infectious Diseases Unit, Hospital Universitario de Cruces,
Bilbao, Spain 5) Infectious Diseases Unit, Hospital Universitario Reina Sofı´a-IMIBIC, Universidad de Co´rdoba, Co´rdaba, Spain 6) Infectious Diseases Unit,
Hospital Ramo´n y Cajal, Madrid, Spain, 7) Infectious Diseases Unit, Hospital Universitario Marque´s de Valdecilla, Santander, Spain, 8) Infectious Diseases
Unit, Hospital Universitario de Bellvitge-IDIBELL, Barcelona, Spain and 9) Infectious Diseases Unit, Hospital General Universitario Gregorio Maran˜o´n, Madrid, Spain
Abstract
Solid organ transplant recipients (SOTR) are at risk of serious inﬂuenza-related complications. The impact of respiratory co-infection in
SOTR with 2009 pandemic inﬂuenza A(H1N1) is unknown. A multicentre prospective study of consecutive cases of pandemic inﬂuenza
A(H1N1) in SOTR was carried out to assess the clinical characteristics and outcome and the risk factors for co-infection. Overall, 51
patients were included. Median time from transplant was 3.7 years, 5.9% of the cases occurred perioperatively and 7.8% were hospital-
acquired. Pneumonia was diagnosed in 15 (29.4%) patients. Ten cases were severe (19.6%): 13.7% were admitted to intensive care units,
5.9% suffered septic shock, 5.9% developed acute graft rejection and 7.8% died. Co-infection was detected in 15 patients (29.4%): eight
viral, six bacterial and one fungal. Viral co-infection did not affect the outcome. Patients with non-viral co-infection had a worse out-
come: longer hospital stay (26.2 ± 20.7 vs. 5.5 ± 10.2) and higher rate of severe diseases (85.7% vs. 2.3%) and mortality (42.8% vs.
2.3%). Independent risk factors for non-viral co-infection were: diabetes mellitus and septic shock. Other factors associated with severe
inﬂuenza were: delayed antiviral therapy, diabetes mellitus, time since transplantation <90 days and pneumonia. In conclusion, pandemic
inﬂuenza A can cause signiﬁcant direct and indirect effects in SOTR, especially in the early post-transplant period, and should be treated
early. Clinicians should be aware of the possibility of non-viral co-infection, mainly in diabetic patients and severe cases. An effort should
be made to prevent inﬂuenza with immunization of the patient and the environment.
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Introduction
In 2009, a new pandemic inﬂuenza A(H1N1) virus was
detected [1,2] and propagated throughout the world [3].
Although severe pandemic inﬂuenza A(H1N1) has been
detected in younger patients compared with seasonal inﬂu-
enza, 20% of cases occurred in immunosuppressed patients
[4,5]. In this setting, solid organ transplant recipients (SOTR)
were included among the risk groups to receive the pan-
demic vaccine [6,7], given the related direct and indirect
morbidity of seasonal inﬂuenza in this population [8].
Recently, a retrospective study has described the demo-
graphic and clinical characteristics and prognostic factors of
intensive care unit (ICU) admission and death in 237 adults
and children with inﬂuenza A and organ transplantation [9].
Other authors, in small series, have observed a longer dura-
tion of symptoms, higher frequency of pneumonia and higher
mortality rate than in the general population [10,11].
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Inﬂuenza viral infection is known to predispose to subse-
quent lung bacterial superinfection [12]. The initial descrip-
tions of severe cases of 2009 pandemic inﬂuenza showed
evidences of primary viral pneumonia with poor relevance of
bacterial co-infection [13–15]. However, in later studies
using PCR and immunochemistry methods, bacterial co-infec-
tion was found in 28–55% of fatal cases [16,17]. Some of the
previous studies in SOTR [9,11] describe the viral or bacte-
rial co-infections, but their impact on the prognosis and clini-
cal care of the inﬂuenza was not analyzed.
The aim of this study was to prospectively assess the clini-
cal characteristics and outcome of pandemic inﬂuenza
A(H1N1) infection in SOTR, and the risk factors for co-
infection by other pathogens.
Methods
Setting, patients and study design
This prospective observational study was conducted at nine
teaching hospitals belonging to the Spanish Network for
Research in Infectious Diseases (REIPI). All SOTR older than
16 years, diagnosed with inﬂuenza A(H1N1), and hospitalized
at the participating centres from June 2009 to January 2010,
were included. A conﬁrmed case was deﬁned in the pres-
ence of inﬂuenza-like illness with laboratory-conﬁrmed 2009
pandemic inﬂuenza A(H1N1) virus infection. The study was
approved by the coordinator local ethics committee and
informed consents were obtained from all subjects.
Clinical assessment and follow-up
In cases of respiratory symptoms, SOTR were advised to
seek care at the hospital. Thereafter, an investigator evalu-
ated and followed them until cure or death in the case of
inﬂuenza diagnosis, and clinical data were recorded in a stan-
dardized protocol. Data were collected on demographic
characteristics, co-morbidities, body mass index (BMI), type
of transplant and immunosuppressive therapy, previous vacci-
nation, clinical signs and symptoms, biochemical analysis,
chest X-ray ﬁndings, antiviral and antibacterial therapy, con-
comitant and/or secondary infection, and outcomes, including
mortality.
Microbiological studies
Pandemic inﬂuenza A(H1N1) was conﬁrmed with RT-PCR
(Inf A/H1N1 Detection, Roche, Basel, Switzerland), in naspo-
pharyngeal smears or aspirates.
Blood cultures, standard studies for bacterial and fungi of
respiratory samples (sputum, bronchial aspirates, bronchoal-
veolar lavage, protected specimen brush and transbronchial
biopsy), and urinary antigen tests for Streptococcus pneumo-
niae and Legionella pneumophila serogroup 1 were performed.
Sputum samples were processed if they contained >25 poly-
morphonuclears and <10 epithelial cells per high-power ﬁeld.
Viral co-infection was investigated in nasopharyngeal sam-
ples using a PCR multiplex RV 12 ACE detection seeplex kit
(Seegene Inc., Seul, Corea) including metapneumovirus, ade-
novirus, coronavirus 229E/NL63 and OC43/HKU1, parainﬂu-
enza virus 1/2/3, rhinovirus A/B, respiratory syncytial viruses
(RSV) A/B, and inﬂuenza virus A/B.
Deﬁnitions
Obesity was deﬁned as a BMI ‡30. Hospital-acquired inﬂuenza
was considered when symptoms began more than 7 days
after admission. Pneumonia was deﬁned by the presence of
clinical symptoms (fever, dyspnoea, cough and/or expectora-
tion) and a new pulmonary inﬁltrate in the chest X-ray for
which other non-infectious causes were excluded. Severity of
pneumonia was assessed by the PSI and CURB-65 scores
[18,19]. Non-viral co-infection was considered if bacteria or
fungi were isolated from blood or respiratory samples, or
with positive urinary antigen detection tests of S. pneumoniae
or L. pneumophila. Severe infections were deﬁned as cases that
were admitted to ICU, developed graft rejection or died.
Statistical analysis
A descriptive analysis was performed. Continuous variables
are expressed as median and range. All proportions were
calculated as percentages of the patients with available data.
The chi-square or Fisher’s exact tests were used for categor-
ical variables and the Student-t, Mann–Whitney and Wilco-
xon tests for continuous variables, when appropriate. The
multivariate logistic regression analysis of factors potentially
associated with non-viral co-infection included signiﬁcant
variables in the univariate analyses and clinically relevant vari-
ables. Statistical signiﬁcance was established at p <0.05 (two-
tailed). The SPSS software (version 15.0; SPSS Inc., Chicago,
IL, USA) was used.
Results
Fifty-one SOTR, with a median age of 48 years (16–73) and
including 28 (54.9%) men were diagnosed with inﬂuenza A
(H1N1). The types of transplant were 24 kidney, 11 liver,
eight lung, ﬁve heart, two combined pancreas-kidney and
one combined liver-kidney. Most patients received triple
therapy with tacrolimus, mycophenolate mofetil and steroids.
One patient had an allograft rejection treated with a cortico-
steroid bolus in the month prior to inﬂuenza. Inﬂuenza
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occurred at 3.7 years after transplantation (1 day to
21.5 years) and in 40 cases (78.4%) occurred beyond the
ﬁrst year (Fig. 1). In three patients (5.9%), symptoms started
1–5 days after the transplant, without identiﬁcation of the
source of inﬂuenza infection; all had pneumonia, one died
and another lost the graft because of acute rejection. Four
cases (7.8%) were hospital acquired.
Co-morbidities, vaccination history and previous use of
antibiotics are detailed in Table 1. Only one patient had
received pandemic inﬂuenza A(H1N1) vaccine, having normal
gammaglobulin levels and no prior rejection episodes.
Clinical manifestations
The most common symptoms were fever (94.1%) and cough
(80.4%). The median delay between the onset of symptoms
and diagnosis was 2 days (1–15). Pneumonia occurred in 15
patients (29.4%). Severity of pneumonia was assessed at
admission with a median PSI of 72 (20–147) and median
CURB-65 score of 1 (0–4). Three and two patients had sep-
tic shock (5.9%) and cardiac failure (3.9%), respectively. The
main clinical manifestations and radiological and analytical
ﬁndings are detailed in Table 2.
At the diagnosis, the only laboratory ﬁndings that differed
from previous basal values were the lymphocyte and platelet
counts (1504 vs. 750/lL (p <0.001) and 193 800 vs. 169 000/
lL (p 0.004), respectively).
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FIG. 1 Pandemic inﬂuenza A(H1N1) virus infection in SOTR. Time
after transplantation.
TABLE 1. Demographics and underlying medical conditions
Variable Value
Male sex, No. (%) 28 (54.9%)
Age in years, median (range) 48 (16–73)
Contact with children <3 years, No. (%) 11 (21.5%)
Tobacco smoker, No. (%) 5 (9.8%)
Type of transplant
Kidney transplant, No. (%) 24 (47.1%)
Liver transplant, No. (%) 11 (21.6%)
Lung transplant, No. (%) 8 (15.7%)
Heart transplant, No. (%) 5 (9.8%)
Combined pancreas-kidney transplant, No. (%) 2 (3.9%)
Combined liver-kidney transplant, No. (%) 1 (1.9%)
Immunosuppression
Ciclosporin, No. (%) 13 (25.4%)
Tacrolimus, No. (%) 31 (60.7%)
Mycophenolate mofetil, No. (%) 38 (74.5%)
m-TOR inhibitors, No. (%) 8 (15.7%)
Azathioprine, No. (%) 1 (1.9%)
Corticosteroids >20 days, No. (%) 30 (58.8%)
Triple immunosuppressive therapy, No. (%) 28 (54.9%)
Double immunosuppressive therapy, No. (%) 21 (41.1%)
Induction therapy in the previous 6 months, No. (%) 3 (5.9%)
Allograft rejection in the previous month, No. (%) 1 (2%)
Co-morbidities 44 (86.3%)
Chronic pulmonary disease, No. (%) 8 (15.7%)
Diabetes mellitus, No. (%) 12 (23.5%)
Chronic heart disease, No. (%) 14 (27.5%)
Cerebrovascular disease, No. (%) 1 (1.9%)
Chronic renal failure, No. (%) 21 (41.5%)
Chronic liver disease, No. (%) 8 (15.7%)
HIV infection, No. (%) 1 (1.9%)
Connective tissue disease, No. (%) 3 (5.9%)
Obesity, No. (%) 2 (3.9%)
Previous vaccines
Seasonal inﬂuenza vaccine 2008/2009, No. (%) 26 (50.9%)
Seasonal inﬂuenza vaccine 2009/2010, No. (%) 24 (47.1%)
Pandemic inﬂuenza A(H1N1) vaccine, No. (%) 1 (1.9%)
Pneumococcal vaccine, No. (%) 19 (37.2%)
Other treatments
Previous antibiotics, No. (%) 5 (9.8%)
Previous statins, No. (%) 17 (33.3%)
Previous angiotensin converter inhibitors, No. (%) 14 (27.4%)
TABLE 2. Clinical, laboratory and radiological ﬁndings in
solid organ transplant recipients at pandemic inﬂuenza A
(H1N1) virus infection diagnosis
Variables Values
Clinical manifestations
Duration of symptoms, median (range) 2 days (1–15 days)
Fever, No. (%) 48 (94.1%)
Temperature, median (range) 38C (35.5–39.8C)
Chills, No. (%) 18 (35.3%)
Cough, No. (%) 41 (80.4%)
Expectoration, No. (%) 19 (37.2%)
Purulent, No. (%) 16 (31.4%)
Mucous, No. (%) 3 (5.9%)
Nasal congestion, No. (%) 11 (21.6%)
Sore throat, No. (%) 6 (11.8%)
Dyspnoea, No. (%) 15 (29.4%)
Arthralgias, No. (%) 32 (62.7%)
Headache, No. (%) 16 (31.4%)
Altered mental status, No. (%) 2 (3.9%)
Diarrhoea, No. (%) 5 (9.8%)
Vomiting, No. (%) 9 (17.6%)
Septic shock, No. (%) 3 (5.9%)
Radiological ﬁndings
Pneumonia, No./Total No. (%) 15 (29.4%)
Alveolar inﬁltrates, No./Total No. (%) 11 (73.3%)
Bilateral inﬁltrates, No./Total No. (%) 11 (73.3%)
Analytical ﬁndings
Partial oxygen saturation <90%, No. (%) 4 (7.8%)
Leukocyte count, per mm3, median (range) 6400 (1800–21450)
<4000/mm3, No. (%) 10 (19.7%)
>12000/mm3, No. (%) 9 (17.6%)
Neutrophil count, per mm3, median (range) 4108 (66–13100)
<1000/mm3, No. (%) 6 (11.7%)
Lymphocyte count, per mm3, median (range) 750 (7–9180)
<1500/mm3 36 (70.5%)
Hematocrit, %, median (range) 37.4 (24.4–53)
<30%, No. (%) 9 (17.6%)
Platelet count, per mm3, median (range) 169000 (230–526000)
<100 000/mm3, No. (%) 7 (13.7%)
AST >40 U/L, No. (%) 10 (19.6%)
ALT >40 U/L, No. (%) 5 (9.8%)
Creatine kinase >100 U/L, No. (%) 3 (5.9%)
Sodium, mEq/L, median (range) 138 (124–146)
Potassium, mEq/L, median (range) 4.3 (2.5–7.1)
Creatinine, mg/dL, median (range) 1.5 (0.6–5.9)
Lactate dehydrogenase, U/L, median (range) 236 (175–496)
Glucose, mg/dL, median (range) 107 (69–285)
C-reactive protein >20 mg/L, No. (%) 11 (21.5%)
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Treatment
All patients received oseltamivir a median of 2 days after the
onset of symptoms (0–16 days), for a median of 5 days (3–
24 days), at a dosage of 75 mg twice daily in all but four
patients, who received 150 mg twice daily. None of the
patients discontinued treatment due to adverse effects. Anti-
biotics were used empirically in 33 patients (64.7%), the
most common being levoﬂoxacin (16 cases, 31.2%) followed
by amoxicillin-clavulanate (8 cases, 15.6%). They were admin-
istered at a median of 5 h after admission (0–96 h) for a
median of 7 days (1–16 days). Decisions regarding adjust-
ment of immunosuppressive therapy were taken by the clini-
cians in charge. In eight severe inﬂuenza cases (16.7%),
corticosteroids were added.
Co-infection
Viral co-infection was evaluated in 32 patients (62.7%). In
eight patients other respiratory viruses were detected: para-
inﬂuenza 2 in two cases, RSV B in two cases, and parainﬂu-
enza 1, parainﬂuenza 3, rhinovirus, adenovirus and RSV A in
one case each.
Non-viral co-infection was detected in seven patients
(13.7%): Staphylococcus aureus in two cases (sputum and
blood/bronchoalveolar lavage), S. aureus (sputum) and Entero-
coccus faecium (blood) in one case, S. pneumoniae in two
cases (blood and urinary antigen detection), Streptococcus viri-
dans in one case (pleural ﬂuid), and Aspergillus fumigatus
(bronchoalveolar lavage) in one case. Factors associated with
the presence of non-viral co-infection were: diabetes mellitus
(57.1% vs. 18.1%, RR 4.2, 95% CI 1.1–16.2, p 0.04), duration
of symptoms at inﬂuenza diagnosis (3 days vs. 2 days,
p 0.03), pneumonia (100% vs. 18.2%, RR undeﬁned,
p <0.001) and septic shock (28.5% vs. 2.3%, RR 6.4, 95% CI
2.0–20.2, p 0.04). No other predictors were observed in
terms of underlying diseases, immunosuppressive therapy,
types of organ, time since transplantation and clinical ﬁndings.
In the multivariate analysis, variables independently related to
non-viral co-infection were diabetes mellitus (OR 16.6, 95%
CI 1.4–197.2, p 0.026) and septic shock (OR 67.2, 95% CI
1.8–2454.8, p 0.022).
Clinical outcomes
The median duration of fever and cough were 2 days (0–10)
and 3 days (0–18), respectively. The median length of hospi-
tal stay was 4 days (2–71). In 10 patients inﬂuenza infection
was severe (19.6%) (Table 3). Seven patients required admis-
sion to ICU (13.7%) for a median of 7 days.
Four patients died (7.8%). Two of them died 4 and 7 days
after inﬂuenza diagnosis, with septic shock and S. aureus bac-
teraemic pneumonia and S. viridans empyema, respectively. A
kidney recipient patient died from pulmonary aspergillosis
31 days after inﬂuenza. The fourth patient, a kidney recipient,
had pneumococcal bacteraemic pneumonia 8 days after inﬂu-
enza diagnosis and Escherichia coli pneumonia 40 days after
inﬂuenza.
Three patients had allograft rejection in the month follow-
ing the inﬂuenza diagnosis: a pancreas recipient and a kidney
recipient transplanted 4 and 2 months ago, respectively, who
responded to a corticosteroid bolus, and a 7-day liver recipi-
ent who lost the graft. Immunosuppressants were not
reduced in any of these patients after inﬂuenza diagnosis.
TABLE 3. Clinical outcomes in solid organ transplant recipi-
ents with pandemic inﬂuenza A (H1N1) virus infection
Variable Value
Duration of fever, days, median (range) 2 (0–10)
Duration of cough, days, median (range) 3 (0–18)
Length of hospital stay, days, median (range) 4 (2–71)
Severe inﬂuenza, No. (%) 10 (19.6%)
Intensive care unit admission, No. (%) 7 (13.7%)
Length of ICU stay, days, median (range) 7 (1–33)
APACHE II score, median (range) 12 (8–24)
Acute respiratory failure, No. (%) 5 (9.8%)
Invasive mechanical ventilation, No. (%) 2 (3.9%)
Allograft rejection, No. (%) 3 (5.9%)
Graft loss, No. (%) 1 (1.9%)
Mortality, No. (%) 4 (7.8%)
TABLE 4. Factors associated with severe pandemic inﬂuenza A(H1N1) virus infection in SOTR
Variable Severe Non-severe RR CI 95% p
Diabetes mellitus, No. (%) 6 (60%) 6 (14.6%) 4.9 (1.6–14.4) 0.007
Time since transplant <90 days, No. (%) 3 (30%) 1 (2.4%) 5.0 (2.1–12.2) 0.02
Septic shock, No. (%) 3 (30%) 0 (0%) 6.8 (3.4–13.6) 0.005
Pneumonia, No. (%) 9 (90%) 6 (14.6%) 21.6 (2.9–155.8) <0.001
Non-viral co-infection, No. (%) 6 (60%) 1 (2.4%) 9.4 (3.5–25.1) <0.001
Time from onset of symptoms to antiviral
therapy, days, median (range)
1 (0–13) 3.5 (1–16) 0.033
Heart rate, bpm, median (range) 97 (70–135) 83.5 (54–130) 0.02
Haematocrit, %, median (range) 29.8 (25–46) 38.8 (24.4–53) 0.01
Serum creatinine, mg/dL, median (range) 1.84 (1.1–5.9) 1.31 (0.6–5.3) 0.04
Bpm: beats per minute.
The chi-square or Fisher’s exact tests were used for categorical variables and the t-test, Mann–Whitney test and Wilcoxon test for continuous variables, when appropriate.
Statistical signiﬁcance was established at a = 0.05. All reported p values are two-tailed.
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Factors related to severe inﬂuenza are detailed in Table 4.
No other predictors were observed in terms of underlying
diseases, previous rejection, immunosuppressive therapy
(type of calcineurin inhibitor, steroids and induction therapy),
types of organ, and clinical manifestations.
Patients with non-viral co-infection had a longer hospital
stay (26.2 ± 20.7 vs. 5.5 ± 10.2, p 0.001), and higher rate of
severe disease (85.7% vs. 2.3%, RR 9.4, 95% CI 3.5–25.2,
p <0.001) and mortality (42.8% vs. 2.3%, RR 18.1, 95% CI
2.3–156.7, p 0.006). The presence of viral co-infection had
no inﬂuence on the outcomes.
Discussion
The present study shows that one-third of SOTR with pan-
demic inﬂuenza had pneumonia, and that mortality is higher
than in the general population [20]. Inﬂuenza infection is
more severe in patients with recent transplants and in those
with delayed onset of antiviral therapy, among other factors.
Besides this, inﬂuenza may be associated with acute allograft
rejection. Co-infections were common in SOTR, and non-
viral co-infections were associated with a worse outcome.
Diabetes mellitus and septic shock were associated with
non-viral co-infections.
The emergence of the pandemic inﬂuenza A virus raised
important questions regarding its impact on the transplant
population, with an expected high associated morbidity and
mortality, as conﬁrmed by this and other studies [9–11].
Seasonal inﬂuenza can occur at any time after the trans-
plant. Vilchez et al. [8] observed a median time since trans-
plantation of 34.5–38.6 months, with the earliest cases
occurring 1.5–2 months after the transplant, in 30 SOTR
with seasonal inﬂuenza. In the case of inﬂuenza A(H1N1),
our data and other studies show that it may occur at any
time after the transplant, with a median time of 27–
44 months [9–11]. Moreover, the present prospective study
shows that some cases occurred in the ﬁrst week after
transplant, and it was associated with a poor prognosis; thus,
two of three patients lost the graft and died, respectively.
Some studies suggested that seasonal inﬂuenza severity and
mortality increase among transplant recipients in the early
post-transplant period [21]. Other studies on pandemic inﬂu-
enza in SORT have not reported data regarding this aspect
[9–11]. In the present study, it was observed that time since
transplantation shorter than 3 months was associated with
severity.
Hospital-acquired seasonal inﬂuenza in SOTR has been
documented [22]. Within the recent pandemic, hospital-
acquired cases of inﬂuenza were reported in immunocom-
promised patients [23], and isolated cases were described in
SOTR [24,25]. In the same way, we found that 8% of the
pandemic inﬂuenza cases were hospital-acquired. Hospital-
acquired inﬂuenza infection in SOTR, even in the early post-
operative period, and the adverse outcomes in cases occur-
ring within the ﬁrst 3 months after the transplant, prompt
some considerations. First, early inﬂuenza diagnosis and
treatment should be considered in the presence of inﬂuenza-
like symptoms, especially in cases of pneumonia, in pandemic
or seasonal inﬂuenza periods, even in the immediate post-
transplant period. Secondly, these patients should be consid-
ered a high-risk population, and therefore measures to avoid
in-hospital transmission should be rigorous, with implementa-
tion of infection control measures, such as isolation of
infected patients, and avoidance of contact with symptomatic
caregivers. In this sense, it is necessary to increase the rate
of vaccination among SOTR and close contacts to confer
indirect protection for those who are non-responders to
vaccine.
In the present study, we found that symptoms and signs
were similar to those described in the general population
[26]. Moreover, SOTR with pandemic inﬂuenza showed fre-
quent haematological and biochemical abnormalities. Some of
them, such as renal failure, mild hepatolysis and anaemia,
were present before inﬂuenza infection and might possibly
be associated with the transplant and concomitant immuno-
suppressive drugs. However, others, such as lymphopenia
and thrombocytopenia, signiﬁcantly worsen after inﬂuenza.
Transplant recipients have more seasonal inﬂuenza-related
complications than the general population, including primary
viral and secondary bacterial pneumonias [8,27]. The propor-
tion of pneumonia in our cohort was in the reported range
(22–49%) in SOTR [9–11]. With respect to the severity of
pneumonia at admission, three of the four cases who died had
a PSI risk class of IV or V; accordingly, the CURB-65 score of
these patients was 2–4. With the limitations of the reduced
number of patients, these data suggest the usefulness of these
severity scores for pneumonia in pandemic inﬂuenza.
In the general population, delayed hospital admission and
antiviral therapy have been associated with an unfavourable
outcome [28–30]. In the present study, time to antiviral
therapy was also associated with severe inﬂuenza, being the
only modiﬁable prognostic factor. These data agree with
those from a retrospective study showing that delayed antivi-
ral therapy is associated with intensive care unit admission
and mortality [9]. It must be noted that most of the patients
included received antiviral therapy within 48 h after the
onset of symptoms, many of them before virological conﬁr-
mation, which might have contributed to an improvement in
the outcome.
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Bacterial pneumonia is a known complication of inﬂuenza.
In the present study, patients with non-viral co-infection, in
contrast to those with viral co-infection, experienced a
worse outcome despite early antibacterial therapy. Risk fac-
tors for non-viral co-infection in patients with pandemic
inﬂuenza A have not been previously described. In this study,
two associated factors at inﬂuenza diagnosis have been iden-
tiﬁed: diabetes mellitus and septic shock. On the other hand,
non-viral co-infections were not diagnosed in mild cases
without pneumonia. These ﬁndings may suggest that non-
severe cases could be managed without antibacterial therapy,
reducing the number of patients exposed to antibiotics, in
our case two-thirds of the patients.
Our data are subject to several limitations. First, as in
other studies carried out in the general population, the data
are from hospitalized patients with pandemic inﬂuenza A.
However, they offer information regarding this illness in
transplant patients with severe disease needing hospital
admission. Second, as susceptibility to oseltamivir was not
performed, we could not conclude whether fatal cases were
related to oseltamivir resistance. Third, the possibility of
graft rejection was only histologically evaluated if it was clini-
cally evident, which could lead to misdiagnoses of mild allo-
graft rejections.
In summary, our ﬁndings indicate that pandemic inﬂuenza
A can not only cause signiﬁcant direct morbidity and mortal-
ity in SOTR, especially in the early post-transplant period,
but also indirect effects with possibly devastating conse-
quences for graft function. Clinicians should be aware of the
possibility of non-viral co-infection in these patients, mainly
in diabetic patients and severe cases. An effort should be
made to increase vaccination among SOTR and caregivers.
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